Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Free Cash Flow (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Free Cash Flow data on record, last reported at -$14.9 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 61.57% year-over-year to -$14.9 million; the TTM value through Dec 2025 reached -$54.4 million, down 49.27%, while the annual FY2025 figure was -$54.4 million, 49.27% down from the prior year.
  • Free Cash Flow reached -$14.9 million in Q4 2025 per PLSE's latest filing, down from -$13.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$6.6 million in Q1 2023 and bottomed at -$16.5 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$11.3 million, with a median of -$11.2 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: crashed 109.21% in 2021, then skyrocketed 58.36% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$12.8 million in 2021, then surged by 37.59% to -$8.0 million in 2022, then rose by 14.75% to -$6.8 million in 2023, then crashed by 34.75% to -$9.2 million in 2024, then tumbled by 61.57% to -$14.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$14.9 million in Q4 2025, -$13.1 million in Q3 2025, and -$12.9 million in Q2 2025.